(ARWR) Arrowhead Pharmaceuticals - Overview
Stock: Plozasiran, Zodasiran, ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.1% |
| Relative Tail Risk | -9.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.86 |
| Alpha | 181.88 |
| Character TTM | |
|---|---|
| Beta | 1.699 |
| Beta Downside | 1.496 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.86% |
| CAGR/Max DD | 0.29 |
Description: ARWR Arrowhead Pharmaceuticals January 13, 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) focuses on RNA-interference (RNAi) therapeutics for hard-to-treat diseases in the U.S. Its lead pipeline features Plozasiran (apoC-III) and Zodasiran (ANGPTL3), both in Phase 3 trials, alongside a suite of early-stage RNAi candidates targeting metabolic and inflammatory pathways (e.g., ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE, ARO-ALK7, ARO-RAGE, ARO-MAPT, ARO-C3, ARO-CFB). The company leverages partnership agreements with GlaxoSmithKline, Takeda, Amgen, and Sarepta to co-develop and commercialize its assets.
As of the latest 10-Q, Arrowhead reported a cash position of roughly $560 million, providing a runway of about 18 months at current burn rates; its market capitalization hovers near $3 billion, and recent Phase 3 interim data for Plozasiran showed a 30 % reduction in triglycerides, a key efficacy signal that could unlock a multi-billion-dollar market if FDA approval is achieved.
The RNAi sector is experiencing rapid growth, driven by the FDA’s expanding acceptance of gene-silencing modalities (e.g., approvals of Alnylam’s Onpattro and GIVLAARI) and a projected CAGR of 20 % through 2030, which underpins strong investor interest and higher valuation multiples for companies with late-stage pipelines.
For a deeper dive into Arrowhead’s valuation dynamics and scenario analysis, you might explore the detailed model on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 202.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 76.46 > 1.0 |
| NWC/Revenue: 75.80% < 20% (prev 1828 %; Δ -1752 % < -1%) |
| CFO/TA 0.21 > 3% & CFO 339.3m > Net Income 202.3m |
| Net Debt (486.1m) to EBITDA (360.3m): 1.35 < 3 |
| Current Ratio: 3.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.7m) vs 12m ago 12.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 83.35% > 50% (prev 2.57%; Δ 80.77% > 0%) |
| Interest Coverage Ratio: 3.72 > 6 (EBITDA TTM 360.3m / Interest Expense TTM 90.2m) |
Altman Z'' 0.26
| A: 0.52 (Total Current Assets 1.17b - Total Current Liabilities 347.4m) / Total Assets 1.60b |
| B: -1.00 (Retained Earnings -1.60b / Total Assets 1.60b) |
| C: 0.26 (EBIT TTM 335.2m / Avg Total Assets 1.31b) |
| D: -1.53 (Book Value of Equity -1.59b / Total Liabilities 1.04b) |
| Altman-Z'' Score: 0.26 = B |
Beneish M 1.00
| DSRI: 2.09 (Receivables 218.9m/2.50m, Revenue 1.09b/26.1m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.44 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 41.82 (Revenue 1.09b / 26.1m) |
| TATA: -0.09 (NI 202.3m - CFO 339.3m) / TA 1.60b) |
| Beneish M-Score: 26.72 (Cap -4..+1) = D |
What is the price of ARWR shares?
Over the past week, the price has changed by -14.19%, over one month by -2.97%, over three months by +57.19% and over the past year by +214.46%.
Is ARWR a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARWR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.7 | 30.4% |
| Analysts Target Price | 81.7 | 30.4% |
| ValueRay Target Price | 68 | 8.5% |
ARWR Fundamental Data Overview February 09, 2026
P/E Forward = 111.1111
P/S = 8.2814
P/B = 15.9045
P/EG = -1.32
Revenue TTM = 1.09b USD
EBIT TTM = 335.2m USD
EBITDA TTM = 360.3m USD
Long Term Debt = 163.1m USD (from longTermDebt, last quarter)
Short Term Debt = 47.5m USD (from shortTermDebt, last quarter)
Debt = 687.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 486.1m USD (from netDebt column, last quarter)
Enterprise Value = 8.81b USD (9.03b + Debt 687.8m - CCE 916.6m)
Interest Coverage Ratio = 3.72 (Ebit TTM 335.2m / Interest Expense TTM 90.2m)
EV/FCF = 27.35x (Enterprise Value 8.81b / FCF TTM 322.0m)
FCF Yield = 3.66% (FCF TTM 322.0m / Enterprise Value 8.81b)
FCF Margin = 29.52% (FCF TTM 322.0m / Revenue TTM 1.09b)
Net Margin = 18.54% (Net Income TTM 202.3m / Revenue TTM 1.09b)
Gross Margin = unknown ((Revenue TTM 1.09b - Cost of Revenue TTM 18.7m) / Revenue TTM)
Tobins Q-Ratio = 5.49 (Enterprise Value 8.81b / Total Assets 1.60b)
Interest Expense / Debt = 3.27% (Interest Expense 22.5m / Debt 687.8m)
Taxrate = 0.10% (29.0k / 28.3m)
NOPAT = 334.8m (EBIT 335.2m * (1 - 0.10%))
Current Ratio = 3.38 (Total Current Assets 1.17b / Total Current Liabilities 347.4m)
Debt / Equity = 1.21 (Debt 687.8m / totalStockholderEquity, last quarter 568.4m)
Debt / EBITDA = 1.35 (Net Debt 486.1m / EBITDA 360.3m)
Debt / FCF = 1.51 (Net Debt 486.1m / FCF TTM 322.0m)
Total Stockholder Equity = 560.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.45% (Net Income 202.3m / Total Assets 1.60b)
RoE = 36.12% (Net Income TTM 202.3m / Total Stockholder Equity 560.0m)
RoCE = 46.35% (EBIT 335.2m / Capital Employed (Equity 560.0m + L.T.Debt 163.1m))
RoIC = 41.69% (NOPAT 334.8m / Invested Capital 803.1m)
WACC = 11.55% (E(9.03b)/V(9.72b) * Re(12.18%) + D(687.8m)/V(9.72b) * Rd(3.27%) * (1-Tc(0.00)))
Discount Rate = 12.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.45%
[DCF Debug] Terminal Value 70.61% ; FCFF base≈322.0m ; Y1≈397.2m ; Y5≈676.5m
Fair Price DCF = 43.65 (EV 6.60b - Net Debt 486.1m = Equity 6.11b / Shares 140.0m; r=11.55% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 6.01 | EPS CAGR: -15.30% | SUE: 0.08 | # QB: 0
Revenue Correlation: 4.81 | Revenue CAGR: 15.90% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.97 | Chg30d=-0.100 | Revisions Net=+2 | Analysts=9
EPS current Year (2026-09-30): EPS=-2.93 | Chg30d=+0.561 | Revisions Net=-1 | Growth EPS=-29236.4% | Growth Revenue=-42.3%
EPS next Year (2027-09-30): EPS=-4.55 | Chg30d=+0.349 | Revisions Net=+2 | Growth EPS=-55.2% | Growth Revenue=-35.3%